Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 8/20 | 0.88 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.88 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.88 |
| ▸ | HRH1 | P35367 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 2/20 | 0.88 |
| ▸ | ESR1 | P03372 | 1/20 | 0.88 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.88 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.88 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.88 |
| ▸ | HRH2 | P25021 | 1/20 | 0.88 |
| ▸ | HTR2A | P28223 | 1/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.88 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.88 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.88 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.88 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL574529 | 0.94 | CHRM3 (0.90) | CHRM3CHRM2CHRM1MAPTCHRM5 | |
| Tolterodine SCHEMBL580446 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1MAPTCHRM5 | |
| Tolterodine SCHEMBL3064 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1MAPTCHRM5 | |
| Tolterodine SCHEMBL29379290 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1MAPTCHRM5 | |
| Tolterodine SCHEMBL36882 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1MAPTCHRM5 | |
| Tolterodine SCHEMBL29635996 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1MAPTCHRM5 | |
| Tolterodine SCHEMBL820421 | 0.94 | CHRM3 (1.00) | CHRM3CHRM2CHRM1MAPTCHRM5 | |
| Tolterodine SCHEMBL3098149 | 0.93 | CHRM3 (1.00) | CHRM3CHRM2CHRM1MAPTCHRM5 | |
| Tolterodine SCHEMBL2403972 | 0.93 | CHRM3 (1.00) | CHRM3CHRM2CHRM1MAPTCHRM5 | |
| Tolterodine SCHEMBL467372 | 0.93 | CHRM3 (1.00) | CHRM3CHRM2CHRM1MAPTCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2338871-B1 | A process for the preparation of fesoterodine with low impurities content | DIPHARMA FRANCIS SRL (IT) | 2013-09-11 | — | — | EP | disclosed |
| US-8455678-B2 | Process for the preparation of fesoterodine with low impurities content | DIPHARMA FRANCIS S.R.L. (IT) | 2013-06-04 | — | — | US | disclosed |
| US-8455678-B2 | Process for the preparation of fesoterodine with low impurities content | DIPHARMA FRANCIS S.R.L. (IT) | 2013-06-04 | — | — | US | disclosed |
| EP-2338871-A1 | A process for the preparation of fesoterodine with low impurities content | Dipharma Francis S.r.l. (IT) | 2011-06-29 | — | — | EP | disclosed |
| EP-2338871-A1 | A process for the preparation of fesoterodine with low impurities content | Dipharma Francis S.r.l. (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-20110152367-A1 | PROCESS FOR THE PREPARATION OF FESOTERODINE WITH LOW IMPURITIES CONTENT | DIPHARMA FRANCIS S.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
| US-20110152367-A1 | PROCESS FOR THE PREPARATION OF FESOTERODINE WITH LOW IMPURITIES CONTENT | DIPHARMA FRANCIS S.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152367-A1 | PROCESS FOR THE PREPARATION OF FESOTERODINE WITH LOW IMPURITIES CONTENT | ADRA2B, ADRA1B, FES | CHRM3 423/4885CHRM2 567/4885CHRM1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.